AMS (American Shared Hospital Services) Q4 2025: LINAC Revenue Surges 35% Amid Leasing Headwinds
American Shared Hospital Services advanced its strategic pivot to direct patient care with strong LINAC treatment volume growth, offsetting declines in leasing revenue due to contract expirations. Operational expansion in Rhode Island and Latin America underpins a growing clinical footprint despite margin pressures and capital structure challenges. Management’s focus on stabilizing physician staffing and expanding treatment centers sets a foundation for long-term growth and improved financial flexibility.
Summary
- Strategic Shift Strengthened: Direct patient care now dominates revenue, reflecting a deliberate transition away from leasing.
- Operational Expansion Driving Growth: Rhode Island and Puebla centers materially increased LINAC treatments and patient access.
- Financial and Capital Challenges: Margin compression and credit covenant breaches highlight near-term risks amid investment cycle.
Business Overview
American Shared Hospital Services (AMS) provides advanced radiation therapy cancer treatment through two primary segments: medical equipment leasing and direct patient care services. The leasing segment supplies stereotactic radiosurgery equipment such as Gamma Knife and proton beam radiation therapy (PBRT) systems to health systems, while the direct patient care segment operates radiation therapy treatment centers offering LINAC (linear accelerator) treatments and Gamma Knife procedures. AMS generates revenue from leasing agreements and patient service fees, with an increasing strategic emphasis on expanding its direct patient care footprint across North and South America.
Performance Analysis
For full year 2025, AMS’s total revenue remained essentially flat at $28.1 million compared to 2024, reflecting a marked shift in revenue composition. Direct patient care services revenue increased 23.7% to $15.5 million, driven by the first full year of operations at three Rhode Island centers and a radiation therapy center in Puebla, Mexico. This growth was underpinned by a 35.4% surge in LINAC revenue to $11.5 million, fueled by a doubling of treatment sessions to 28,147. Conversely, the medical equipment leasing segment faced headwinds with revenue declining to $12.6 million from $15.6 million, primarily due to the expiration of three Gamma Knife contracts and a 26% fall in PBRT revenue to $7.4 million.
Margins contracted significantly, with gross margin falling to 18% for the year from 32% in 2024, reflecting both the lower-margin nature of direct patient care services and reduced leasing volumes. The fourth quarter exemplified these trends with revenue down 14.8% year-over-year to $7.7 million, leasing revenue dropping 33.9%, and gross margin compressing to 12%. Despite these pressures, net loss narrowed to $631,000 in Q4 from $1.3 million a year prior, supported by operational improvements and revenue cycle enhancements. Capital expenditures of $7.5 million during 2025, largely for Rhode Island expansion and international upgrades, contributed to a cash balance decline to $3.7 million and triggered credit covenant breaches, prompting ongoing lender negotiations.
- Revenue Mix Evolution: Direct patient care now comprises 63% of Q4 revenue, up from 52% last year.
- Volume Growth Offset Leasing Declines: LINAC treatment volumes more than doubled, while Gamma Knife procedures rose on a same-center basis following equipment upgrades.
- Margin Pressure from Strategic Transition: Shift to lower-margin patient services and contract expirations reduced gross margins materially.
In sum, AMS’s 2025 financials reflect a company in transition, balancing growth investments and operational expansion with legacy leasing segment headwinds and margin challenges.
Executive Commentary
"2025 was the foundational year for American Shared Hospital Services as we expanded our direct patient care services platform and strengthened the operational infrastructure needed to support long-term growth... Our priorities going forward are clear. Increase treatment volumes across our existing centers, drive operational efficiencies and margin improvement, expand our footprint through disciplined development, and continue to leverage our partnerships to scale our platform."
Gary Delanis, President and Chief Executive Officer
"We continue to be our foundation to our business and a key driver of our long-term strategy... Our longstanding partnership of over two decades with Orlando Health highlights the long-term nature of the Company’s relationships and reflects the ongoing collaboration in delivering advanced cancer treatment services."
Ray Stachowiak, Executive Chairman
Strategic Positioning
1. Accelerated Shift to Direct Patient Care Services
AMS is deliberately transitioning from a leasing-heavy model to one where direct patient care services constitute the majority of revenue. This shift provides more stable, recurring revenue streams and greater control over clinical operations. The expansion of stand-alone radiation therapy centers in Rhode Island and Puebla, Mexico, has been central to this strategy, enabling AMS to increase LINAC treatment volumes substantially and broaden patient access.
2. Operational Expansion and Clinical Capacity Building
The company is actively growing its geographic footprint with certificate of need approvals for a new radiation therapy center in Bristol, Rhode Island, and a proton beam therapy center in Johnston, Rhode Island. These projects are expected to come online in late 2027 and 2028, respectively, and are designed to leverage existing clinical infrastructure and personnel to manage costs during ramp-up phases. Internationally, upgrades such as the Gamma Knife Esprit platform in Lima, Peru, and development of a Guadalajara center further diversify AMS’s clinical presence.
3. Partnership-Driven Growth Model
Longstanding collaborations with health systems, including a renewed seven-year lease with Orlando Health for proton therapy, underpin AMS’s growth. These partnerships facilitate capital sharing, operational synergies, and physician recruitment, exemplified by the relationship with Brown University Health Care New England to stabilize radiation oncology staffing. This partnership model mitigates risk and supports scalability.
4. Capital Structure Optimization and Liquidity Management
AMS invested $7.5 million in capital expenditures during 2025, reflecting its growth initiatives but leading to cash depletion and covenant breaches under its credit facility. Management is engaged in constructive discussions with lenders to amend terms and secure financial flexibility. Prudent capital allocation and improved cash flow generation are priorities to sustain operational momentum and fund expansion.
5. Technology Upgrades to Enhance Treatment Capabilities
Equipment upgrades, including the Gamma Knife Esprit platform, have improved treatment capabilities, allowing AMS to treat a broader range of diagnoses and increase same-center procedure volumes. While these upgrades temporarily distort year-over-year comparisons due to downtime, they position AMS for longer-term volume growth and competitive differentiation.
Key Considerations
AMS’s 2025 results highlight the balancing act between growth investment and near-term financial performance amid strategic transition.
- Revenue Mix Shift: The growing share of direct patient care revenue signals a durable strategic pivot but comes with margin trade-offs.
- Leasing Segment Headwinds: Contract expirations and cyclical PBRT volume fluctuations continue to pressure leasing revenue and margins.
- Capital Intensity and Cash Flow: Significant capex spending and lower operating cash flow have strained liquidity and triggered covenant breaches.
- Operational Execution: Stabilization of physician staffing and revenue cycle improvements are critical to sustaining volume growth and financial recovery.
- Partnership Leverage: Collaborations with health systems remain integral to clinical expansion and risk mitigation.
Risks
Risks include ongoing reimbursement uncertainties, potential delays in new center openings, operational execution risks in ramping clinical volumes, and the need for successful negotiations with lenders to amend credit covenants. The company’s transition exposes it to margin compression and cash flow volatility, which require careful management to avoid liquidity constraints.
Forward Outlook
For Q1 2026, AMS anticipates continued volume growth at existing centers, particularly in Rhode Island and international markets, supported by operational improvements and upgraded equipment. Management did not provide explicit financial guidance but emphasized focus on improving cash flow and margin expansion.
- Anticipated ramp-up of new centers in Rhode Island starting late 2027.
- Ongoing efforts to optimize revenue cycle management and control operating expenses.
Management highlighted that constructive lender discussions remain ongoing to secure financial flexibility necessary for executing growth initiatives.
Takeaways
AMS’s fourth quarter and full year 2025 results reveal a company actively reshaping its business model toward direct patient care services, with meaningful volume growth offset by legacy leasing segment challenges and margin pressure.
- Strategic Transition Driving Volume and Revenue Mix: The doubling of LINAC treatments and 24% revenue growth in direct patient care underscore successful operational expansion and patient access improvements.
- Financial Strain from Investment Cycle: Margin compression and cash depletion highlight the cost of growth and the importance of capital structure optimization to sustain momentum.
- Execution and Partnership as Growth Enablers: Stabilizing physician staffing and leveraging health system partnerships are critical to scaling the platform and mitigating operational risks.
Conclusion
American Shared Hospital Services is navigating a pivotal transformation from a leasing-centric model to a direct patient care services platform. While near-term financial metrics reflect margin and liquidity pressures, the company’s expanding clinical footprint, strategic partnerships, and technology investments position it for sustainable long-term growth. Execution on operational efficiencies and capital management will be key to realizing this potential.
Industry Read-Through
AMS’s experience highlights broader radiation therapy industry trends, including the shift toward integrated care delivery models that emphasize direct patient services over equipment leasing. The company’s strategic investments in clinical capacity and technology upgrades echo sector-wide moves to enhance treatment capabilities and patient access. Additionally, the challenges with reimbursement dynamics and capital intensity are common across healthcare providers expanding advanced oncology services. Other participants should monitor AMS’s approach to partnership-driven growth and capital structure management as a case study in balancing innovation with financial discipline.